931 results on '"Vandrey, Ryan"'
Search Results
2. Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC)
3. Mobile App-Delivered Cognitive Behavioral Therapy for Insomnia: Feasibility and Initial Efficacy Among Veterans With Cannabis Use Disorders
4. Smoking abstinence and cessation-related outcomes one month after an immediate versus gradual reduction in nicotine content of cigarettes.
5. Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain
6. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis
7. Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder
8. Perceived reward from using cigarettes with alcohol or cannabis and concurrent use: A smartphone-based daily diary study
9. Factors that Impact the Pharmacokinetic and Pharmacodynamic Effects of Cannabis: a Review of Human Laboratory Studies
10. Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers.
11. Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers.
12. A cross-sectional survey on cannabis: Characterizing motives, opinions, and subjective experiences associated with the use of various oral cannabis products
13. Real-Time Monitoring of Cannabis and Prescription Opioid Co-Use Patterns, Analgesic Effectiveness, and the Opioid-Sparing Effect of Cannabis in Individuals With Chronic Pain
14. Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects
15. Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein.
16. Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation.
17. Likelihood of Positive Urine Screens of THC-COOH After Daily Use of Full-Spectrum Hemp Extracts Varies as a Function of Screening Criterion Used
18. Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial
19. Effects of Reduced Nicotine Content Cigarettes on Individual Withdrawal Symptoms Over Time and During Abstinence
20. Cannabinoids for Agitation in Alzheimer's Disease
21. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples
22. Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy
23. The Impact of Gradual and Immediate Nicotine Reduction on Subjective Cigarette Ratings
24. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults
25. Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes
26. Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms.
27. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model
28. Estimations and predictors of non‐compliance in switchers to reduced nicotine content cigarettes
29. Feasibility and acceptability of using smartphone-based EMA to assess patterns of prescription opioid and medical cannabis use among individuals with chronic pain
30. Cannabis Withdrawal
31. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies
32. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda
33. Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis
34. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users
35. Measuring the temporal association between cannabis and tobacco use among Co-using young adults using ecological momentary assessment
36. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products
37. The psychedelic effects of cannabis: A review of the literature
38. Changing landscape of cannabis: novel products, formulations, and methods of administration
39. Randomized Trial of Reduced-Nicotine Standards for Cigarettes
40. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder
41. S140 - I Crave Not to Feel Uncomfortable: Craving for Opioids and Cannabis Among Patients With Chronic Pain
42. S17 - Evaluation of the Pharmacokinetic and Pharmacodynamic Profile of Cannabigerol (CBG) in Human Subjects
43. DOSE EFFECTS OF ORAL AND VAPORIZED DELTA-8-THC AND COMPARISON TO DELTA-9-THC IN HEALTHY ADULTS
44. WITHIN-SUBJECT, DOUBLE-BLIND HUMAN LABORATORY EVALUATION OF CANNABIDIOL ON OPIOID-INDUCED ANALGESIA AND SUBJECTIVE EFFECTS
45. Sleep Management Among Patients with Substance Use Disorders
46. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration
47. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
48. Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
49. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults
50. The psychedelic effects of cannabis: A review of the literature.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.